ABT-263

• CAT Number: I005495
• CAS Number: 923564-51-6
• Molecular Formula: C₄₅H₅₅ClF₃N₅O₆S₃
• Molecular Weight: 974.61
• Purity: ≥95%
• Synonyms: ABT-263;ABT263
• Target: Bcl-2 Family
• Solubility: DMSO ≥190mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL
• Storage: -20℃
• IC50: ≤ 0.5 nM(Ki for Bcl-xL); ≤1 nM(Ki for Bcl-2); ≤1 nM(Ki for Bcl-w)
• IUPAC Name: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
• InChI: InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29
• InChIKey: JLYAXFNOILIKPP-KXQOOQHDSA-N
• SMILES: CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

ABT-263(Cat No.: I005495), also known as navitoclax, is a potent, orally bioavailable inhibitor of BCL-2 family proteins, including BCL-2, BCL-XL, and BCL-W. It works by promoting apoptosis in cancer cells, particularly in hematological cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. ABT-263 has shown promising anti-cancer activity in clinical trials, though its use is limited by dose-dependent thrombocytopenia (platelet depletion). Ongoing studies are evaluating its combination with other therapies for enhanced efficacy and safety.